Research programme: neurobehavioural disorders therapeutics - BlackThorn Therapeutics

Drug Profile

Research programme: neurobehavioural disorders therapeutics - BlackThorn Therapeutics

Alternative Names: BTRX Program 2; BTRX Program 3; BTRX Program 4; BTRX-335140; BTRX-395750

Latest Information Update: 17 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BlackThorn Therapeutics
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 06 Apr 2017 Pharmacodynamics data from a preclinical trial in Neurological disorders released by BlackThorn Therapeutics
  • 20 Oct 2016 Preclinical trials in Neurological disorders in USA (unspecified route) (BlackThorn Therapeutics pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top